Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtre
Ajouter des filtres








Gamme d'année
1.
Obstetrics & Gynecology Science ; : 709-718, 2020.
Article Dans Anglais | WPRIM | ID: wpr-902919

Résumé

Objective@#The need for tailoring ovarian cancer treatments to individual patients is increasing. This study aimed to evaluate the prognostic value of pretreatment laboratory test data for predicting the response and survival outcomes of platinumbased chemotherapy in ovarian cancer. @*Methods@#We enrolled 270 patients with ovarian cancer diagnosed at the Kyoto Medical Center (n=120; group A) and Kyoto University (n=150; group B). Data on 9 blood parameters (neutrophil to lymphocyte ratio [NLR], platelet to lymphocyte rate [PLR], C-reactive protein, lactate dehydrogenase [LDH], glucose, total cholesterol, high-density lipoprotein [HDL], low-density lipoprotein, and triglyceride levels), cancer pathology, cancer stage, cytoreduction outcomes, serum cancer antigen 125 levels, platinum-free interval (PFI), disease-free survival (DFS), and overall survival were assessed retrospectively. @*Results@#NLR, PLR, LDH, and HDL were significantly different in advanced stage patients (P<0.001, <0.001, 0.029, and <0.001, respectively). The Kaplan-Meier curves revealed that high LDH level (≥250 U/L) was associated with reduced PFI (P=0.037 and 0.012) and DFS (P=0.007 and 0.002) in groups A and B, respectively. High NLR (≥4) was associated with reduced DFS in both groups (P=0.036 and 0.005, respectively). LDH showed higher area under the curve (AUC) values in predicting platinum resistance with a PFI of less than 6 months and 12 months (AUC=0.606 and 0.646, respectively) than NLR. In the multivariate analysis, LDH remained significant (P=0.019) after adjusting for the 9 blood parameters. @*Conclusion@#Serum LDH level may possibly predict platinum resistance and prognosis in ovarian cancer and may be useful when developing precision medicine for individual patients.

2.
Obstetrics & Gynecology Science ; : 709-718, 2020.
Article Dans Anglais | WPRIM | ID: wpr-895215

Résumé

Objective@#The need for tailoring ovarian cancer treatments to individual patients is increasing. This study aimed to evaluate the prognostic value of pretreatment laboratory test data for predicting the response and survival outcomes of platinumbased chemotherapy in ovarian cancer. @*Methods@#We enrolled 270 patients with ovarian cancer diagnosed at the Kyoto Medical Center (n=120; group A) and Kyoto University (n=150; group B). Data on 9 blood parameters (neutrophil to lymphocyte ratio [NLR], platelet to lymphocyte rate [PLR], C-reactive protein, lactate dehydrogenase [LDH], glucose, total cholesterol, high-density lipoprotein [HDL], low-density lipoprotein, and triglyceride levels), cancer pathology, cancer stage, cytoreduction outcomes, serum cancer antigen 125 levels, platinum-free interval (PFI), disease-free survival (DFS), and overall survival were assessed retrospectively. @*Results@#NLR, PLR, LDH, and HDL were significantly different in advanced stage patients (P<0.001, <0.001, 0.029, and <0.001, respectively). The Kaplan-Meier curves revealed that high LDH level (≥250 U/L) was associated with reduced PFI (P=0.037 and 0.012) and DFS (P=0.007 and 0.002) in groups A and B, respectively. High NLR (≥4) was associated with reduced DFS in both groups (P=0.036 and 0.005, respectively). LDH showed higher area under the curve (AUC) values in predicting platinum resistance with a PFI of less than 6 months and 12 months (AUC=0.606 and 0.646, respectively) than NLR. In the multivariate analysis, LDH remained significant (P=0.019) after adjusting for the 9 blood parameters. @*Conclusion@#Serum LDH level may possibly predict platinum resistance and prognosis in ovarian cancer and may be useful when developing precision medicine for individual patients.

3.
Journal of the Japanese Association of Rural Medicine ; : 106-110, 2019.
Article Dans Japonais | WPRIM | ID: wpr-758116

Résumé

A questionnaire was administered to identify differences between the information that ward nurses think should be provided on a discharge summary and the information that outpatient nurses consider is necessary for providing continuing nursing care. Respondents were asked to select from multiple choice answers which information they believe is necessary to provide on a discharge summary and their perceptions about continuing nursing care, and they were also asked to record the reasons for their selections. Multiple choice responses were aggregated by simple tabulation and reasons were aggregated by similarity. The results showed that ward nurses and outpatient nurses had the same perceptions of what information is needed on a discharge summary. However, whereas the outpatient nurses wanted to see specific information about what care should be continued on the discharge summary, the ward nurses considered continuing nursing care to mean sharing summarized information about the patient's hospital course. This difference can be attributed to the unique characteristics of ward nurses and outpatient nurses. To provide continuing nursing care, ward nurses and outpatient nurses should each understand the other's thinking and learn what information the other considers necessary.

SÉLECTION CITATIONS
Détails de la recherche